Prodrugs for improved ocular drug delivery

Advanced Drug Delivery Reviews

Volumn 19, Issue 2, 1996, Pages 203-224

  Järvinen, Tomi ^a   Järvinen, Kristiina ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Bioactivation; Corneal penetration; Drug delivery; Ester; Lipophilicity; Ocular absorption; Ocular prodrug; Stability

Indexed keywords

ABSORPTION; ANTIBIOTICS; CHEMICAL ACTIVATION; DISEASES; DRUG THERAPY; ENZYME INHIBITION; TOXICITY;

BIOACTIVATION; BIOAVAILABILITY; CORNEAL PENETRATION; EYEDROPS; IMPROVED OCULAR DRUG DELIVERY; LIPOPHILICITY; OCULAR ABSORPTION; PRODRUG DERIVATIZATION; PRODRUGS; PROSTAGLANDINS;

DRUG PRODUCTS;

ACICLOVIR; ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DIPIVEFRINE; FLUOROURACIL; IDOXURIDINE; NADOLOL; OXPRENOLOL; PHENYLEPHRINE; PILOCARPINE; PRODRUG; PROSTAGLANDIN; SALBUTAMOL; STEROID; TILISOLOL; TIMOLOL;

ARTICLE; DERIVATIZATION; DRUG ABSORPTION; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG SOLUBILITY; DRUG STABILITY; EYE DISEASE; LIPOPHILICITY; PHARMACEUTICS; PRIORITY JOURNAL;

EID: 0343026463     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00107-I     Document Type: Review

References (155)

1. Lee, V.H.L. and Robinson. J.R. (1986) Review: Topical ocular drug delivery: Recent developments and future challenges. J. Ocul. Pharmacol. 2, 67-108.
2. Greaves, J.L., Olejnik, O. and Wilson, C.G. (1992) Polymers and the precorneal tear film. STP Pharm. Sci. 2, 13-33.
3. Urtti, A. and Salminen, L. (1993) Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. 37, 435-456.
4. Stella, V.J. and Himmelstein, K.J. (1980) Prodrugs and sife-spectfic drug delivery. J. Med. Chem. 23, 1275-1282.
5. Sinkula, A.A. and Yalkowsky, S.H. (1975) Rationale for desing of biologically reversible drug derivatives: Pro-drugs. J. Pharm. Sci. 64, 181-210.
6. Bodor, N., El-Koussi, A.A., Kano, M. and Khalifa, M.M. (1988) Soft drugs. 7. Soft β-blockers for systemic and ophthalmic use. J. Med. Chem. 31, 1651-1656.
7. Bodor, N. (1985) Prodrugs versus soft drugs. In: H. Bundgaard. (Ed.), Design of Prodrugs, Elsevier, Amsterdam, pp. 333-354.
8. Bodor, N. and Visor, G. (1984) Improved delivery through biological membranes. XVII, A site-specific chemical delivery system as a short-acting mydriatic agent. Pharm. Res. 4, 168-173.
9. Bodor, N., ElKoussi, A., Kano, M. and Nakamura, T. (1988) Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for β-adrenergic blocking agents. J. Med. Chem. 31, 100-106.
10. El-Koussi, A. and Bodor, N. (1989) Formation of propanol in the iris-ciliary body from its propanol ketoxime precursor - a potential antiglaucoma drug. Int. J. Pharm. 53, 189-194.
11. Bodor, N. and Elkoussi, A. (1991) Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime - a new potential antiglaucoma agent. Pharm. Res. 8, 1389-1395.
12. Polgar, P. and Bodor, N. (1995) Minimal cardiac electro-physiological activity of alprenoxime, a site-activated ocular β-blocker, in dogs. Life Sci. 56, 1207-1213.
13. Reddy, I.K. and Bodor, N.S. (1994) Novel approaches to design and deliver safe and effective antiglaucoma agents to the eye. Adv. Drug Deliv. Rev. 14, 251-267.
14. Visor G.C. (1994) Drug design strategies for ocular therapeutics. Adv. Drug Deliv. Rev. 14, 269-279.
15. Bodor, N. (1994) Designing safer ophthalmic drugs by soft drug approaches. J. Ocul. Pharmacol. 10, 3-15.
16. Lee, V.H.L. and Li, V.H.K. (1989) Prodrugs for improved ocular drug delivery. Adv. Drug Deliv. Rev. 3, 1-38.
17. Lee, V.H.L. and Bundgaard, H (1992) Improved ocular drug delivery with prodrugs. In: K.B. Sloan (Ed.), Drugs and the Pharmaceutical Sciences, Vol. 53: Prodrugs, Topical and Ocular Drug Delivery, Marcel Dekker, Inc., New York, pp. 221-297.
18. Lee, V.H.L. and Robinson, J.R. (1979) Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. J. Pharm. Sci. 68, 673-684.
19. Maurice, D.M. and Mishima, S. (1984) Ocular pharmacokinetics. In: M.C. Sears (Ed.) Handbook of Experimental Pharmacology, Vol. 69, Pharmacology of the Eye, Springer-Verlag, Berlin, pp. 19-116.
20. Doane, M.G., Jensen, A.D. and Dohlman, C.H. (1978) Penetration routes of topically applied eye medications. Am. J. Ophthalmol. 85, 383-386.
21. Ahmed, I. and Patton, T.F. (1985) Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 26, 584-587.
22. Ahmed, I. and Patton, T.F. (1987) Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption. Int. J. Pharm. 38, 9-21.
23. Grass, G.M. and Robinson, J.R. (1988) Mechanisms of corneal drug penetration 11: Ultrastructural analysis of potential pathways for drug movement. J. Pharm. Sci. 77, 15-23.
24. Liaw, J. and Robinson, J.R. (1993) Ocular penetration enhancers. In: A.K. Mitra (Ed.), Ophthalmic Drug Delivery Systems, Marcel Dekker, Inc. New York, pp. 369-381.
25. Schoenwald, R.D. and Huang, H-S. (1983) Corneal penetration behavior of beta-blocking agents I: Physico-chemical Factors. J. Pharm. Sci. 72, 1266-1272.
26. Liaw, J. and Robinson, J.R. (1992) The effect of polyethylene glycol molecular weight on corneal transport and the related influence of penetration enhancers. Int. J. Pharm. 88, 125-140.
27. Huang, A.J.W., Tseng, S.C.G. and Kenyon, K.R. (1989) Paracellular permeability of corneal and conjunctival epithelia. Invest. Ophthalmol. Vis. Sci. 30, 684-689.
28. Rojanasakul. Y., Wang, L.-Y., Bhat, M., Glover, D.D., Malanga, C.J. and Ma, K.H. (1992) The transport barrier of epithelia: A comparative study on membrane permeability and charge selectivity in the rabbit. Pharm. Res. 9, 1029-1034.
29. Liaw, J.L. Rojanasakul, Y. and Robinson, J.R. (1992) The effect of drug charge type and charge density on corneal transport. Int. J. Pharm. 88, 111-124.
30. Sieg, J.W. and Robinson, J.R. (1977) Vehicle effects on ocular drug bioavailability II: Evaluation of pilocarpine, J. Pharm. Sci. 66, 1222-1228.
31. Maren, T.H. and Jankowska, L. (1985) Ocular pharmacology of sulfonamides: the cornea as barrier and depot. Curr. Eye Res. 4, 399-408.
32. Brechue, W.F. and Maren, T.H. (1993) pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors. Invest. Ophthalmol. Vis. Sci. 34, 2581-2587.
33. Borchardt, R.T. (1990) Assesment of transport barriers using cell and tissue culture systems. Drug Dev. Ind. Pharm. 16, 2595-2612.
34. Chien, D.-S., Sasaki, H., Bundgaard, H., Buur, A. and Lee, V.H.L. (1991) Role of enzymatic lability in the corneal and conjunctiva! penetration on timolol ester prodrugs in the pigmented rabbit. Pharm. Res. 8, 728-733.
35. Schoenwald, R.D. and Ward, R.L. (1978) Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. J. Pharm. Sci. 67, 787-789.
36. Mosher, G.L. and Mikkelson, T.J. (1979) Permeability of the alkyl p-aminobenzonate esters across the isolated corneal membrane of the rabbit. Int. J. Pharm. 2, 239-243.
37. Wang, W., Sasaki, H., Chien, D-S. and Lee, V.H.L. (1991) Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: A comparison with corneal penetration. Curr. Eye Res. 10, 571-579.
38. Shih, R.-U. and Lee, V.H.L. (1990) Rate limiting barrier to the penetration of ocular hypotensive beta blockers across the corneal epithelium in the pigmented rabbit. J. Ocul. Pharmacol. 6, 329-336.
39. Suhonen, P., Järvinen, T., Peura, P. and Urtti, A. (1991) Permeability of pilocarpic acid diesters across albino rabbit cornea in vitro. Int. J. Pharm. 74, 221-228.
40. Suhonen, P., Järvinen, T., Rytkönen, P., Peura, P. and Urtti, A. (1991) Improved corneal pilocarpine permeability with O,O′-(1,4-xylylene) bispilocarpic acid ester double prodrugs. Pharm. Res. 8, 1539-1542.
41. Friedrich, S.W., Cheng, Y.-L. and Saville, B.A. (1993) Theoretical corneal permeation model for ionizable drugs. J. Ocul. Pharmacol. 9, 229-249.
42. Rojanasakul, Y. and Robinson, J.R. (1989) Transport mechanism of the cornea: characterization of barrier permselectivity. Int. J. Pharm. 55, 237-246.
43. Petersen, R.A., Lee, K.J. and Donn, A. (1965) Acetyl-cholinesterase in the rabbit cornea. Arch. Ophthalmol. 73, 370-377.
44. Lee, V.H.L., Chang, S.-C., Oshiro, C.M. and Smith, R.E. (1985) Ocular esterase composition in albino and pigmented rabbits: possible implications in ocular prodrug design and evaluation. Curr. Eye Res. 4, 1117-1125.
45. Lönnerholm, G. (1974) Carbonic anhydrase in the cornea. Acta Physiol. Scand. 90, 143-152.
46. Armstrong, J., Myers, D.V., Verpoorte, J.A. and Edsall, J.T. (1966) Purification and properties of human erythrocyte carbonic anhydrases. J. Biol. Chem. 241, 5137-5149.
47. Harris, D., Liaw, J.-H. and Robinson, J.R. (1992) Routes of delivery: case studies. (7) Ocular delivery of peptide and protein drugs. Adv. Drug Deliv. Rev. 8, 331-339.
48. Stratford, R.E. Jr. and Lee, V.H.L. (1986) Aminopeptidase activity in homogenates of various absorptive mucosae in the albino rabbit: implications in peptide delivery. Int. J. Pharm. 30, 73-82.
49. Schive, K. and Volden, G. (1982) Characterization and quantification of acid phosphatase and glycoside hydrolases in rabbit cornea. Acta Ophthalmol. 60, 590-598.
50. Lojda, Z., Cejkova, J., Bolkova, A. and Havrankova, E. (1976) Uneven distribution of alkaline phosphatase in individual layers of rabbit and of cornea. Histochemistry 49, 237-243.
51. Lee, V.H.L. (1983) Esterase activities in adult rabbit eyes. J. Pharm. Sci. 72, 239-244.
52. Redell, M.A., Yang, D.C. and Lee, V.H.L. (1983) The role of esterase activity in the ocular disposition of dipivalyl epinephine in rabbits. Int. J. Pharm. 17, 299-312.
53. Lee, V.H.L., Stratford, Jr., R.E. and Morimoto, K.W. (1983) Age-related changes in esterase activity in rabbit eyes. Int. J. Pharm. 13, 183-195.
54. Lee, V.H.L., Morimoto, K.W. and Stratford, Jr., R.E. (1982) Esterase distribution in the rabbit cornea and its implications in ocular drug bioavailability. Biopharm. Drug Dispos. 3, 291-300.
55. Bundgaard, H. (1989) The double prodrug concept and its applications. Adv. Drug Deliv. Rev. 3, 39-65.
56. 2α esters across cornea in vitro. Int. J. Pharm. 29, 259-266.
57. Chang, S.-C. and Lee, V.H.L. (1982/1983) Influence of chain lenght on the in vitro hydrolysis of model ester prodrugs by ocular esterases. Curr. Eye Res. 2, 651-656.
58. Järvinen, T., Poikolainen, M., Suhonen, P., Vepsäläinen, J., Alaranta, S. and Urtti, A. (1995) Comparison of enzymatic hydrolysis of pilocarpine prodrugs in human plasma, rabbit cornea and butyrylcholinesterase solutions. J. Pharm. Sci. 84, 656-660.
59. Anderson, J.A., Davis, W.L. and Wei, C.-P. (1980) Site of ocular hydrolysis of a prodrug, dipivefrin, and comparison of its ocular metabolism with that of the parent compound, epinephrine. Invest. Ophthalmol. Vis. Sci. 19, 817-823.
60. Hussain, A. and Truelove, J.E. (1976) Prodrug approaches to enhancement of physicochemical properties of drugs. IV: Novel epinephrine prodrug. J. Pharm. Sci. 65, 1510-1512.
61. Mandell, A.I. and Stentz, F. (1978) Dipivalyl epinephrine: A new pro-drug in the treatment of glaucoma. Ophthalmology 85, 268-275.
62. Wei, C., Anderson, J.A. and Leopold, I. (1978) Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine. Invest. Ophthalmol. Vis. Sci. 17, 315-321.
63. Kaback, M.B., Podos, S.M., Harbin, Jr., T.S., Mandell, A. and Becker, B. (1976) The effects of dipivalyl epinephrine on the eye. Am. J. Ophthalmol. 81, 768-772.
64. Anderson, J.A. (1980) Systemic absorption of topical ocularly applied epinephrine and dipivefrin. Arch. Ophthalmol. 98, 350-353.
65. Kohn, A.N., Moss, A.P., Hargett, N.A., Ritch, R., Smith, H. and Podos, S.M. (1979) Clinical comparison of dipivalyl epinephrine and epinephrine in the treatment of glaucoma. Am. J. Ophthalmol. 87, 196-201.
66. Salminen, L., Krootila, K., Helin, H. and Hakala, T. (1995) Corneal vascularization and opacification during long-term use of dipivefrin. J. Ocul. Pharmacol. Ther. 11, 37-40.
67. Schoenwald, R.D., Folk, J.C., Kumar, V. and Piper, J.G. (1987) In vivo comparison of phenylephrine and phenylephrine oxazolidine instilled in the monkey eye. J. Ocul. Pharmacol. 3, 333-340.
68. Miller-Meeks, M.J., Farrell, T.A., Munden, P.M., Folk, J.C., Rao, C. and Schoenwald, R.D. (1991) Phenylephrine prodrug, report of clinical trials. Ophthalmology 98, 222-226.
69. Chien, D.S. and Schoenwald, R.D. (1986) Improving the ocular absorption of phenylephrine. Biopharm. Drug Dispos. 7, 453-462.
70. Schoenwald, R.D. and Chien, D.S. (1987) Ocular absorption and disposition of phenylephrine and phenylephrine oxazolidine. Biopharm. Drug Dispos. 9, 527-538.
71. Chien, D.-S. and Schoenwald, R.D. (1990) Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes. Pharm. Res. 7, 476-483
72. Yuan, S.-S. and Bodor, N. (1976) Synthesis and activity of (R)-(-)-m-trimethylacetoxy-α-[(methylamino)-methyl]benzyl alcohol hydrochloride: A prodrug form of (R)-(-)-phenylephrine. J. Pharm. Sci. 65, 929-931.
73. Mindel, J.S., Shaikewitz, S.T. and Podos, S.M. (1980) Is phenylephrine pivalate a prodrug? Arch. Ophthalmol. 98, 2220-2223.
74. 2α on aqueous humor dynamics of rabbit, cat, and monkey. Invest. Ophthalmol. Vis. Sci. 25, 1087-1093.
75. Bito, L.Z., Draga, A., Blanco, J. and Camras, C.B. (1983) Long-term maintenance of reduced intraocular pressure by daily twice daily topical application of prostaglandins to cat of rhesus monkey eyes. Invest. Ophthalmol. Vis. Sci. 24, 312-319.
76. 2α- in the human eye. Graefes Arch. Clin. Exp. Ophthalmol. 222, 139-141.
77. 2α on intraocular pressure in normotensive human subjects. Invest. Ophthalmol. Vis. Sci. 29: 1474-1477.
78. Bito, L.Z. (1987) Prostaglandins, old concepts and new perspectives. Arch. Ophthalmol. 105, 1036-1039.
79. 2α-1-isopropyl ester. Exp. Eye Res. 44, 217-226.
80. 2α-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma. Br. J. Ophthalmol. 73, 975-979.
81. Camras, C.B., Siebold, E.C., Lustgarten, J.S., Serie, J.B., Frisch, S.C., Podos, S.M., and Bito, L.Z., (1989) Maintained reduction of multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 96, 1329-1337.
82. 2α ester prodrugs and receptor selective prostaglandin analogs. J. Ocul. Pharmacol. 10, 177-193.
83. 2α. Br. J. Ophthalmol. 78, 560-567.
84. Woodward, D.F. and Chan. M.F. (1992) Recent developments in glaucoma therapy. Curr. Opin. Ther. Pat. 2/3, 287-304.
85. Resul, B., Stejernschantz, J., No. K., Liljebris, C., Selén, G., Astin, M., Karlsson, M. and Bito, L.Z. (1993) Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agents. J. Med. Chem. 36, 243-248.
86. Aim, A., Villumsen, J., Törnquist, P., Mandahl, A., Airaksinen, J., Tuulonen, A., Marsk, A., Resul, B. and Stjernschantz, J. (1993) Intraocular pressure-reducing effect of PHXA41 in patients with increased eye pressure. Ophthalmology 100, 1312-1317.
87. 2α isopropyl ester: potential anti-glaucoma agents. J. Med. Chem. 38, 289-304.
88. Sugrue, M.F. (1989) The pharmacology of antiglaucoma drugs. Pharmacol. Ther. 43, 91-138.
89. Nelson, W.L., Fraunfelder, F.T., Sills, J.M., Arrowsmith, J.B. and Kuritsky, J.N. (1986) Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution 1978-1985. Am. J. Ophthahnol. 102, 606-611.
90. Bundgaard, H., Buur, A., Chang, S.-C. and Lee, V.H.L. (1988) Timolol prodrugs: synthesis, stability and lipophilicity of various alkyl, cycloalkyl and aromatic esters of timolol. Int. J. Pharm. 46, 77-88.
91. Urtti, A., Pipkin, J.D., Rork, G., Sendo, T., Finne, U. and Repta, A.J. (1990) Controlled drug delivery devices for experimental ocular studies with timolol. 2. Ocular and systemic absorption in rabbits. Int. J. Pharm. 61, 241-249.
92. Bundgaard, H., Buur, A., Chang, S-C. and Lee, V.H.L. (1986) Prodrugs of timolol for improved ocular delivery: synthesis, hydrolysis kinetics and lipophilicity of various timolol esters. Int. J. Pharm. 33, 15-26.
93. Bundgaard, H., Buur, A. and Lee, V.H.L. (1988) Timolol prodrugs: preparation and hydrolysis kinetics of N-benzoyl carbamate esters of timolol and related compounds. Acta Pharm. Suec. 25, 293-306.
94. Chien, D-S., Sasaki, H., Bundgaard, H., Buur, A. and Lee, V.H.L. (1991) Role of Enzymatic lability in the corneal and conjunctival penetration of timolol ester prodrugs in the pigmented rabbit. Pharm. Res. 8, 728-733.
95. Chang, S.-C., Bundgaard, H., Buur, A. and Lee, V.H.L. (1987) Improved corneal penetration of timolol by prodrugs as a means to reduce systemic drug load. Invest. Ophthalmol. Vis. Sci. 28, 487-491.
96. Chang, S.-C., Bundgaard, H., Buur, A. and Lee, V.H.L. (1988) Low dose O-butyryl timolol improves the therapeutic index of timolol in the pigmented rabbit. Invest. Ophthalmol. Vis. Sci. 29, 626-629.
97. Chang, S.-C., Chien, D.-S., Bundgaard, H. and Lee, V.H.L. (1988) Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol. Exp. Eye Res. 46, 59-69.
98. Potter, D.E., Shumate, D.J., Bundgaard, H. and Lee, V.H.L. (1988) Ocular and cardiac β-antagonism by timolol prodrugs, timolol and levobunolol. Curr. Eye Res. 7, 755-759.
99. Pitha, J., Milecki, J., Fales, H., Pannell, L. and Uekama, K. (1986) Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs. Int. J. Pharm. 29, 73-82.
100. Stella, V.J. and Rajewski, R.A. (1992) Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof. US Patent 5 134-127.
101. Pech, B., Chetoni, P., Saettone, M.F., Duval, O. and Benoit, J.-P. (1993) Preliminary evaluation of a series of amphiphilic timolol prodrugs: possible evidence for transscleral absorption. J. Ocul. Pharmacol. 9, 141-150.
102. Alexander, J., Cargill, R., Michelson, S.R. Schwam, H. (1988) (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: Increased penetration through biological membranes. J. Med. Chem. 31, 318-322.
103. Schoenwald, R.D. and Huang, H-S. (1983) Corneal penetration behavior of β-blocking agents. I: Physico-chemical factors. J. Pharm. Sci. 72, 1266-1272.
104. Duzman, E., Chen, C-C., Anderson, J., Blumenthal, M. and Twizer, H. (1982) Diacetyl derivative of nadolol: I. Ocular pharmacology and short-term ocular hypotensive effect in glaucomatous eyes. Arch. Ophthalmol. 100, 1916-1919.
105. Duzman, E., Rosen, N. and Lazar, M. (1983) Diacetyl nadolol: 3-month ocular hypotensive effect in glaucomatous eyes. Br. J. Ophthalmol. 67, 668-673.
106. Sasaki, H., Igarashi, Y., Nishida, K. and Nakamura, J. (1993) Ocular delivery of the β-blocker, tilisolol, through the prodrug approach. Int. J. Pharm. 93, 49-60.
107. Jordan, C.G.M., Quigley, J.M. and Timoney, R.F. (1992) Synthesis, hydrolysis kinetics and lipophilicity of O-acyl esters of oxprenolol. Int. J. Pharm. 84, 175-189.
108. Bundgaard, H., Falch, E., Larsen, C. and Mikkelson, T.J. (1986) Pilocarpine prodrugs. I: synthesis, physicochemical properties and kinetics of lactonization of pilocarpic acid esters. J. Pharm. Sci. 75, 36-43.
109. Bundgaard, H., Falch, E., Larsen, C., Mosher, G.L. and Mikkelson, T.J. (1985) Pilocarpic acid esters as novel sequentially labile pilocarpine prodrugs for improved ocular delivery. J. Med. Chem. 28, 979-981.
110. Bundgaard, H., Falch, E., Larsen, C., Mosher, G.L. and Mikkelson, T.J. (1986) Pilocarpine prodrugs. II: synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters. J. Pharm. Sci. 75, 775-783.
111. Mosher, G.L., Bundgaard, H., Falch, E., Larsen, C. and Mikkelson, T.J. (1987) Ocular bioavailability of pilocarpic acid mono- and diester prodrugs as assessed by miotic activity in the rabbit. Int. J. Pharm. 39, 113-120.
112. Mosher, G.L. (1986) Theoretical and experimental evaluation of pilocarpine prodrugs for ocular delivery. Ph.D. Thesis, The University of Kansas, KS.
113. Weinkam, R.J., WaldeMussie, E., Ruiz, G., Feldmann, B., Dino, J., Ismail, I. and Bundgaard, H. (1990) Pilocarpine prodrugs: O-benzoyl pilocarpic acid methyl ester ocular metabolism and effects on miosis and intraocular pressure. Pharm. Res. (Suppl.) 7, 64.
114. Järvinen, T., Suhonen, P., Auriola, S., Vepsäläinen, J., Urtti, A. and Peura, P. (1992) Bispilocarpic acid mono-esters as prodrugs of pilocarpine: I. Preparation and identification. Int. J. Pharm. 79, 233-242.
115. Järvinen, T., Suhonen, P,. Auriola, S., Vepsäläinen, J., Urtti, A. and Peura, P, (1991) O,O′-(1,4-Xylylene) bispilocarpic acid esters as new potential double pro-drugs of pilocarpine for improved ocular delivery. I. Synthesis and analysis. Int. J. Pharm. 75, 249-258.
116. Järvinen, T., Suhonen, P., Auriola, S., Vepsäläinen, J., Urtti, A. and Peura, P. (1992) Synthesis and analysis of O,O′-dicarboxylate (dibenzyl) bispilocarpates as possible prodrugs of pilocarpine. J. Pharm. Biomed. Anal. 10, 153-161
117. - pine: II. Physicochemical properties and kinetics of hydrolysis in aqueous solution. Int. J. Pharm. 79, 243-250.
118. Järvinen, T., Suhonen, P., Urtti, A. and Peura, P. (1991) O,O′-(1.4-Xylylene) bispilocarpic acid esters as new potential double prodrugs of pilocarpine for improved ocular delivery, II. Physicochemical properties, stability, solubility and enzymatic hydrolysis. Int. J. Pharm. 75, 259-269.
119. Järvinen, T., Suhonen, P., Launonen, M., Peura, P. and Urtti, A. (1992) Lipophilicity, aqueous solubility, stability and enzymatic hydrolysis of various O,O′-dicarboxylate (dibenzyl) bispilocarpates as possible prodrugs of piloarpine for ophthalmic administration. STP Pharm. Sci. 2, 53-60.
120. Konschin, H. and Ekholm, M. (1991) Molecular modeling of pilocarpine prodrugs: a theoretical investigation of pilocarpic acid esters. Int. J. Quantum Chem. Quantum Biol. Symp. 18, 247-267.
121. Suhonen, P., Järvinen, T., Lehmussaari, K., Reunamäki, T. and Urtti A. (1995) Rate control of ocular pilocarpine delivery with bispilocarpic acid diesters. Int. J. Pharm., in press.
122. Suhonen, P., Järvinen, T., Lehmussaari, K., Reunamäki, T. and Urtti, A. (1995) Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in eyedrop. Pharm. Res. 12, 529-533.
123. Järvinen, T., Järvinen, K., Urtti, A., Thompson, D. and Stella, V.J. (1995) Sulfobutyl ether β-cyclodextrin (SBE-β-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. J. Ocul, Pharmacol. Ther. 11, 95-106.
124. Nakanishi, K., Masada, M., Nadai, T. and Miyajima, K. (1989) Effect of the interaction of drug-β-cyclodextrin complex with bile salts on the drug absorption from rat small intestinal lumen. Chem. Pharm. Bull. 37, 211-214.
125. Frijlink, H.W., Eissens, A.C., Schoonen, A.J.M. and Lerk, C.F. (1990) The effect of cyclodextrins on drugs absorption II. In vivo observation. Int. J. Pharm. 64, 195-205.
126. Druzgala, P., Winwood, D., Drewniak-Deyrup, M., Smith, S., Bodor, N. and Kaminski, JJ. (1992) New water-soluble pilocarpine derivatives with enhanced and sustained muscarinic activity. Pharm. Res. 9, 372-377.
127. Bodor, N.S. (1977) Selected quaternary ammonium salts of pilocarpine useful in reducing intraocular pressure in warm-blooded animals. US Patent 4,061,722.
128. Epstein, D. and Grant, W.M. (1977) Carbonic anhydrase inhibitor side effects. Arch. Ophthalmol. 95, 1378-1382.
129. Lichter, P.R., Lawrence, P., Newman, P., Wheeler, N.C. and Beall, O.V. (1978) Patient tolerance to carbonic anhydrase inhibitors. Am. J. Ophthalmol. 85, 495-502.
130. Loftsson, T., Fridriksdóttir, H., Thórisdóttir, S., Stefánsson, E., Sigurdardóttir, A.N., Gudmundsson, Ö. and Sigthórsson, T. (1994) 2-Hydroxypropyl-β-cyclodextrin in topical carbonic anhydrase inhibitor formulations. Eur. J. Pharm. Sci. 1, 175-180.
131. Javitt, J.C., Javitt, N.B. and McDonnell, P. (1994) Topical compositions for the eye comprising a beta-cyclodextrin derivative and a carbonic anhydrase inhibitor. PCT Patent Publication WO 94/15582.
132. Sugrue, M.F., Gautheron, P., Schmitt, C.,Viader, M.P., Conquet, P., Smith, R.L., Share, N.N. and Stone, C.A. (1985) On the pharmacology of L-645, 151: A topically effective ocular hypotensive carbonic anhydrase inhibitor. Pharmacol. Exp. Ther. 232, 534-540.
133. Grove, J., Gautheron, P., Plazonnet, B. and Sugrue, M.F. (1988) Ocular distribution studies of the topical carbonic anhydrase inhibitors L-643,799 and L-650,719 and related alkyl prodrugs. J. Ocul. Pharmacol. 4, 279-290.
134. Woltersdorf, O.W., Schwam, H., Bicking, J.B. Brown, S.L., de Solms, S.J. Fishman, D.R., Graham, S.L., Gautheron, P.D., Hoffman, J.M., Larson, R.D., Lee, W.S., Michelson, S.R., Robb, C.M., Share, N.N., Shepard, K.L., Smith, A.M., Smith, R.L., Sondey, J.M., Strohmaier, K.M., Sugrue, M.F., Viader, M.P., (1989) Topically active carbonic anhydrase inhibitors. 1. O-Acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide. J. Med. Chem. 32, 2486-2492.
135. Schoenwald, R.D. and Barfknecht, C.F. (1991) Pro-drugs of carbonic anhydrase inhibitors. Eur. Patent Appl. 0 419 311 A2.
136. Surgue, M.F., Gautheron, P., Mallorga, P., Nolan, T.E., Graham, S.L., Schwam, H., Shepard, K.L. and Smith, R.L. (1990) L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals, Br. J. Pharmacol. 99, 59-64.
137. Surgue, M.F., Mallorga, P., Schwam. H., Baldwin, J.J. and Ponticello, G.S. (1990) A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr. Eye Res. 9, 607-615.
138. Lippa, E.A., Aasved. H., Airaksinen, J., Aim, A., Bertelsen, T., Calissendorff, B., Dithmer, O., Eriksson, L.-O., Gustad, L., Hovding, G., Mönestam, E., Krogh, E., Deasy, D., Panebianco, D., Tuulonen, A., (1991) Multiple-dose, dose-response relationship for the topical carponic anhydrase inhibitor MK-927. Arch. Ophthalmol. 109, 46-49.
139. Schaeffer, H.J., Beauchamp, L., Miranda, P., Elion, G.B., Bauer, D.J. and Collins, P. (1978) 9-(2-Hydroxy-ethoxymethyl)guanine activity against viruses of the herpes group. Nature 272, 583-585.
140. Colla, L., De Clercq, E., Busson, R. and Vanderhaeghe, H. (1983) Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxy-ethoxy)methyl]guanine]. J. Med. Chem. 26, 602-604.
141. Maudgal, P., De Clercq, K., Descamps, J. and Missotten, L. (1984) Topical treatment of experimental herpes simplex keratouveits with 2′-O-glycylacyclovir. Arch. Ophthalmol. 102, 140-142.
142. Bundgaard, H., Jensen, E. and Falch, E. (1991) Water-soluble, solution-stable, and biolabile N-substituted (aminomethyl)benzoate ester prodrugs of acyclovir, Pharm. Res. 8, 1087-1093.
143. Jensen, E. and Bundgaard, H. (1991) Kinetics of the acid-catalyzed hydrolysis of acyclovir and an ester prodrug in aqueous solution. Acta Pharm. Nord. 3, 147-150.
144. Hughes, P.M., Krishnamoorthy, R. and Mitra, A.K. (1993) Effect of acylation on the ocular disposition of acyclovir. I: synthesis, physicochemical properties, and antiviral activity of 2′-esters. J. Ocul. Pharmacol. 9, 287-297.
145. Hughes, P.M. and Mitra, A.K. (1993) Effect of acylation on the ocular disposition of acyclovir II: Corneal permeability and anti-HSV 1 activity of 2′-esters in rabbit epithelial keratitis. J. Ocul. Pharmacol. 9, 299-309.
146. Narurkar, M.M. and Mitra, A.K. (1989) Prodrugs of 5-iodo-2′-deoxyuridine for enhanced ocular transport. Pharm. Res. 6, 887-891.
147. Kupferman, A., Berrospi, A.R. and Leipowitz, H.M. (1982) Fluorometholone Acetate. A new ophthalmic derivative of fluorometholone. Arch. Ophthalmol. 100, 640-641.
148. Leibowitz, H.M., Berrospi, A.R., Kupferman, A., Restropo, G.V., Galvis, V. and Alvarez, J.A. (1977) Penetration of topically administered prednisolone acetate into the human aqueous humor. Am. J. Ophthalmol. 83, 402-406.
149. Kupferman, A., Pract, M.V., Suckewer, K. and Leibowitz, H.M. (1974) Topically applied steroids in corneal disease. III. The role of drug derivatives in stromal absorption of dexamethasone. Arch. Ophthalmol. 91, 373-376.
150. Cox, W.V., Kupferman, A. and Leipowitz, H.M. (1972) Topically applied steroids in corneal disease. II. The role of drug vehicle in stromal absorption of dexamethasone. Arch. Ophthalmol. 88, 549-552.
151. Musson, D., Bidgood, A. and Olejnik, O. (1989) In vitro penetration and metabolism studies of prednisolone phosphate, disodium and prednisolone acetate across the cornea of rabbits. Pharm. Res. (Suppl.) 6, S-175.
152. Musson, D., Bidgood, A. and Olejnik, O. (1991) Comparative corneal penetration of prednisolone sodium phosphate and prednisolone acetate in NZW rabbits. J. Ocul. Pharmacol. 7, 175-182.
153. Leibowitz, H.M. and Kupferman A. (1978) Evaluation of dexamethasone acetate as a topical ophthalmic formulations. Am. J. Ophthalmol. 86, 418-423.
154. Chetoni, P., Crotti, P. and Saettone, M.F. (1994) Albuterol prodrugs for ocular administration: synthesis and evaluation of the physico-chemical and IOP-depressant properties of three albuterol triesters. Int. J. Pharm. 105, 147-155.
155. Wang, W., Bundgaard, H., Buur, A. and Lee, V.H.L. (1991) Corneal penetration of 5-fluorouracil and its improvement by prodrug derivatization in the albino rabbit: implication in glaucoma filtration surgery. Curr. Eye Res. 10, 87-97.